淺談化學治療引起周邊神經性病變之護理照護

Nursing Care of Chemotherapy-Induced Peripheral Neuropathy

10.6224/JN.62.2.84

徐書儀(Shu-Yi Hsu)；呂長賢(Chang-Hsien Lu)；陳淑真(Shu-Zhen Chen)；簡淑慧(Sui-Whi Jane)

癌症患者 ； 化學治療 ； 周邊神經病變 ； cancer patient ； chemotherapy ； peripheral neuropathy

護理雜誌

62卷2期（2015 / 04 / 01）

84 - 88

繁體中文

化學治療引起周邊神經性病變（chemotherapyinducedperipheral neuropathy, CIPN）為接受神經毒性藥物如：紫杉醇類（taxanes）、鉑類（platinum）、長春花鹼類（vinca alkaloids）患者常見副作用，其會出現遠端肢體難以忍受的對稱性麻木、燒灼及刺痛感，嚴重影響病人生活功能及生活品質，嚴重時需降低藥量甚至中斷治療，故醫護人員應重視此議題。文獻查證發現，目前相關文獻對於CIPN照護文章較缺乏，故本文旨在協助護理人員瞭解化學治療引起之周邊神經性病變之臨床表徵、致病機轉、臨床評估及照護，適度強化患者肌力、平衡訓練及預防跌倒因子，以減緩症狀嚴重度並確保安全，進而提升此族群病人之生活品質。

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event occurring in patients who receive neurotoxic chemotherapeutic agents such as taxanes, platinum, and vinca alkaloids. The manifestations of CIPN include intolerable symmetric numbness, burning and tingling in distal limbs, disruption of daily functions, reduced quality of life, and the reduction in dosage or discontinued use of these agents. There is a paucity of articles on nursing care related to CIPN in the literature. This article reviews the pathophysiology, clinical presentation, diagnostic criteria, medical management and nursing care of CIPN. Review findings are intended to help nurses identify high-risk groups in order to implement preventive measures that strengthen the muscles, train the balance, and initiate falling precautions of persons in this population. Timely preventive measures may effectively alleviate CIPN symptoms and assure the safety and overall quality of life of patients.

1. Argyriou, A. A.,Koltzenburg, M.,Polychronopoulos, P.,Papapetropoulos, S.,Kalofonos, H. P.(2008).Peripheral nerve damage associated with administration of taxanes in patients with cancer.Critical Reviews in Oncology/Hematology,66(3),218-228.
2. Armstrong, T.,Almadrones, L.,Gilbert, M. R.(2005).Chemotherapy- induced periperal neuropathy.Oncology Nuring Forum,32(2),305-311.
3. Bennett, M.(2001).The LANSS pain scale: The Leeds assessment of neuropathic symptoms and signs.Pain,92(1-2),147-157.
4. Bouhassira, D.,Attal, N.,Alchaar, H.,Boureau, F.,Brochet, B.,Bruxelle, J.,Vicaut, E.(2005).Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).Pain,114(1-2),29-36.
5. Bouhassira, D.,Attal, N.,Fermanian, J.,Alchaar, H.,Gautron, M.,Masquelier, E.,Boureau, F.(2004).Development and validation of the neuropathic pain symptom inventory.Pain,108(3),248-257.
6. Carlson, K.,Ocean, A. J.(2011).Peripheral neuropathy with microtubule-targeting agents: Occurrence and management approach.Clinical Breast Cancer,11(2),73-81.
7. Cleeland, C. S.,Farrar, J. T.,Hausheer, F. H.(2010).Assessment of cancer-related neuropathy and neuropathic pain.The Oncologist,15(2, Suppl.),13-18.
8. Driessen, C. M.,de Kleine-Bolt, K. M.,Vingerhoets, A. J.,Mols, F.,Vreugdenhil, G.(2012).Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: The introduction of a new measure.Supportive Care in Cancer,20(4),877-881.
9. Galer, B. S.,Jensen, M. P.(1997).Development and preliminary validation of a pain measure specific to neuropathic pain: The neuropathic pain scale.Neurology,48(2),332-338.
10. Hausheer, F. H.,Schilsky, R. L.,Bain, S.,Berghorn, E. J.,Lieberman, F.(2006).Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.Seminars in Oncology,33(1),15-49.
11. Krause, S. J.,Backonja, M. M.(2003).Development of a neuropathic pain questionnaire.The Clinical Joural of Pain,19(5),306-314.
12. National Comprehensive Cancer Network. (2013). NCCN clinical practice guidelines for adult cancer pain version 2.2013. Retrieved from http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf
13. Ocean, A. J.,Vahdat, L. T.(2004).Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies.Supportive Care in Cancer,12(9),619-625.
14. Portenoy, R.(2006).Development and testing of a neuropathic pain screening questionnaire: ID pain.Current Medical Research and Opinion,22(8),1555-1565.
15. Sioka, C.,Kyritsis, A. P.(2009).Central and peripheral nervous system toxicity of common chemotherapeutic agents.Cancer Chemotherapy and Pharmacology,63(5),761-767.
16. Storey, D. J.,Sakala, M.,McLean, C. M.,Phillips, H. A.,Dawson, L. K.,Wall, L. R.,Clive, S.(2010).Capecitabine combined with oxaliplatin (CapOX) in clinical practice: How singificanct is peripheral neuropathy?.Annals of Oncology,21(8),1657-1661.
17. Tofthagen, C.,McAllister, R. D.,McMillan, S. C.(2011).Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.Clinical Journal of Oncology Nursing,15(2),182-188.
18. Tofthagen, C.,Visovsky, C. M.,Hopgood, R.(2013).Chemotherapy-induced peripheral neuropathy: An algorithm to guide nursing management.Clinical Journal of Oncology Nursing,17(2),138-144.
19. Tofthagen, C.,Visovsky, C.,Berry, D. L.(2012).Strength and balance training for adults with peripheral neuropathy and high risk of fall: Current evidence and implications for future research.Oncology Nursing Forum,39(5),416-424.
20. Wickham, R.(2007).Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice.Clinical Joural of Oncology Nursing,11(3),361-376.
21. Wong, R.,Sagar, S.(2006).Acupuncture treatment for chemotherapy-induced peripheral neuropathy-A case series.Acupuncture in Medicine,24(2),87-91.
22. 國民健康署（2014）．民國100年癌症登記報告．取自http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx-?No=201404160001 [Health Promotion Administration, Taiwan, ROC. (2014). 2011 cancer report. Retrieved from http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201404160001]
23. 楊榮森, R. S.(2008)。老年人的跌倒與骨折預防。台灣老年醫學暨老年學雜誌，3(2)，78-90。
24. 蔡婷芳, T. F.(2008)。臺北市=Taiwan, ROC，國立台灣大學護理學研究所=National Taiwan University。

1. 陳繪竹,陳遴鞠,胡馨方,李文馨(2018)。一位青壯年直腸癌併急性腸阻塞病人之護理經驗。志為護理-慈濟護理雜誌，17(5)，123-132。
2. 蘇靖幃、許心恬、孫婉娜、申子蘋(2018)。運用實證探討口服麩醯胺對癌症病人接受化學治療引起的周邊神經病變之成效。護理雜誌，65(1)，61-69。
3. 楊婷婷,紀慧真(2021)。一位乳癌手術患者首次接受化學治療引起周邊神經病變之護理經驗。腫瘤護理雜誌，21(增訂刊II)，57-68。